Clinical Trial

A Rollover Study for Subjects Who Completed Participation in IMSA101-101 Trial

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated November 18, 2024 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a rollover study from parent protocol IMSA101-101 for adult patients with advanced malignancies that were previously receiving IMSA101 and who would continue to receive benefit with study treatment of IMSA101 in combination with an immune checkpoint inhibitor (ICI).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-08-30; most recent amendment 2024-11-14.
Status change: Not Yet Recruiting → Active, Not Recruiting 2023-10-10
Trial Details
NCT Number NCT06026254
Lead Sponsor ImmuneSensor Therapeutics Inc.
Conditions Solid Tumor, Adult
Enrollment 2 participants
Start Date 2023-09-15
Primary Completion 2025-09 (estimated)
Study Completion 2025-09 (estimated)
Updated on ClinicalTrials.gov 2024-11-18